SAN DIEGO–(BUSINESS WIRE)–Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to remlifanserin, an investigational, highly selective, 5-HT2A receptor inverse agonist, for the treatment of hallucinations and delusions associated with Alzheimer’s disease psychosis (ADP). Fast Track designation is designed to facilitate the development and expedite the review of drugs intended to treat serious conditions a
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
